Monopar Therapeutics Inc (MNPR) has shared an announcement.
Monopar Therapeutics Inc. has made significant progress in its MNPR-101 radiopharmaceutical program, leading to the filing of a provisional patent application to protect these recent advancements. This development could signal promising future prospects for the company and its stakeholders in the field of medical radiotherapeutics.
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.
